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ORIGINAL INVESTIGATION
Cohort comparison study of cardiac 
disease and atherosclerotic burden in type 2 
diabetic adults using whole body cardiovascular 
magnetic resonance imaging
Suzanne L. Duce1†, Jonathan R. Weir‑McCall1,2*† , Stephen J. Gandy2,3, Shona Z. Matthew1, Deirdre B. Cassidy1, 
Lynne McCormick1, Petra Rauchhaus4, Helen Looker5, Helen M. Colhoun5 and J. Graeme Houston1,2
Abstract 
Background: Whole body cardiovascular MR (WB CVMR) combines whole body angiography and cardiac MR assess‑
ment. It is accepted that there is a high disease burden in patients with diabetes, however the quantification of the 
whole body atheroma burden in both arterial and cardiac disease has not been previously reported. In this study we 
compare the quantified atheroma burden in those individuals with and without diabetes by clinical cardiovascular 
disease (CVD) status.
Methods: 158 participants underwent WB CVMR, and were categorised into one of four groups: (1) type 2 diabetes 
mellitus (T2DM) with CVD; (2) T2DM without CVD; (3) CVD without T2DM; (4) healthy controls. The arterial tree was 
subdivided into 31 segments and each scored according to the degree of stenosis. From this a standardised atheroma 
score (SAS) was calculated. Cardiac MR and late gadolinium enhancement images of the left ventricle were obtained 
for assessment of mass, volume and myocardial scar assessment.
Results: 148 participants completed the study protocol—61 % male, with mean age of 64 ± 8.2 years. SAS was 
highest in those with cardiovascular disease without diabetes [10.1 (0–39.5)], followed by those with T2DM and CVD 
[4 (0–41.1)], then those with T2DM only [3.23 (0–19.4)] with healthy controls having the lowest atheroma score [2.4 
(0–19.4)]. Both groups with a prior history of CVD had a higher SAS and left ventricular mass than those without 
(p < 0.001 for both). However after accounting for known cardiovascular risk factors, only the SAS in the group with 
CVD without T2DM remained significantly elevated. 6 % of the T2DM group had evidence of silent myocardial infarct, 
with this subcohort having a higher SAS than the remainder of the T2DM group [7.7 (4–19) vs. 2.8 (0–17), p = 0.024].
Conclusions: Global atheroma burden was significantly higher in those with known cardiovascular disease and with‑
out diabetes but not in those with diabetes and cardiovascular disease suggesting that cardiovascular events may 
occur at a lower atheroma burden in diabetes.
Keywords: Whole body MRI, Magnetic resonance angiography, CMR, LVA, WB CVMR, Cardiovascular disease, 
Atherosclerosis, Atheroma score, Type 2 diabetes mellitus, T2DM
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Background
Type 2 diabetes mellitus (T2DM) is a chronic metabolic 
disease resulting in an inability to control glucose home-
ostasis due to insulin resistance. It accounts for over 90 % 
of all diabetes cases [1], and in many western countries 
it is reaching epidemic proportions due to an ageing 
population, increasing prevalence of obesity and sed-
entary lifestyles [2]. There are several clinical complica-
tions associated with diabetes which include macro- and 
micro-vascular disorders such as stroke, coronary heart 
disease, peripheral vascular disease as well as nephropa-
thy and retinopathy [3]. These conditions can impose an 
immense burden on the quality of life of individuals with 
diabetes [4].
The systemic nature of atherosclerosis is widely appre-
ciated with disease in one arterial territory predictive 
of disease in another, with this effect particularly pro-
nounced in diabetes [5]. Thus the ability to assess the 
whole body burden of this disease process is desirable 
in an effort to greater understand macro-vascular dis-
ease burden and behaviour in diabetes, as well as to 
help quantify future risk, target treatments and monitor 
response. Whole body cardiovascular magnetic reso-
nance imaging (WB CVMR) combines cardiac magnetic 
resonance (CMR) and whole body MR angiography (WB-
MRA) sequences to produce high spatial and temporal 
resolution images of the cardiovascular system with cov-
erage from the head to the feet [6]. It has been shown to 
be effective at systemically quantifying the presence and 
severity of cardiac disease and atherosclerosis across the 
arterial network in patients with cardiovascular disease 
in single examination taking of the order of 45  min [7]. 
WB-MRA in a diabetic population has been previously 
demonstrated to be a feasible single examination for 
ascertaining cardiovascular disease distribution, detect-
ing occult disease and quantifying stenotic burden, and 
for these findings to provide strong prognostic informa-
tion of future cardiovascular events [8, 9].
While previous studies have documented the burden 
of vascular disease in people with diabetes, to date no 
study has focussed on the impact of type 2 diabetes on 
the whole body atheroma burden combining quantita-
tive of both WB-MRA and CMR. Thus we aimed to com-
pare the effects of type 2 diabetes and individuals without 
CVD on the quantitative atherosclerotic burden through-
out the body in those with and without known cardiovas-
cular disease.
Methods
Ethical approval
The East of Scotland Research Ethics Committee 
approved the protocols. The study was conducted at 
in accordance with the Declaration of Helsinki. The 
volunteers gave written informed consent to participate 
in this study.
Participants
The study was a single centre observational sub-study of 
the multicentre SUrrogate markers for Micro- and Mac-
rovascular hard endpoints for Innovative diabetes Tools 
(SUMMIT) study. 158 volunteers were recruited, with 
148 completing the WB-CVMR protocol between March 
2009 and December 2012.
The participants were recruited from the UK Type 2 
Diabetes Case–Control Collection Wellcome study and 
via the Scottish Primary Care Research network, the 
Scottish Diabetes Research network, Secondary Care 
Diabetes clinics, and through advertising such as post-
ers and leaflets. After clinical evaluation, the subjects 
were categorised into four groups based on their history 
of type 2 diabetes and cardiovascular disease as follows: 
Group 1 type 2 diabetes mellitus (T2DM) with a prior 
clinical diagnosis of cardiovascular disease that included 
coronary artery disease (CAD), cerebrovascular disease 
and/or lower extremity arterial disease (LEAD); Group 2 
type 2 diabetes mellitus with no clinical evidence of car-
diovascular disease; Group 3 absence of diabetes mellitus 
with clinical evidence of CAD, cerebrovascular disease 
and/or LEAD; Group 4 healthy controls, with no bio-
chemical evidence of diabetes mellitus (see below) and 
no clinical evidence of cardiovascular disease.
The inclusion criteria for Groups 1 and 2 (with T2DM) 
was T2DM diagnosis after the age of 35 and no require-
ment for insulin injection for 12 months after diagnosis. 
The non-diabetic status of those in Groups 3 and 4 were 
confirmed by testing their haemoglobin A1C (HbA1C) 
levels, with inclusion criteria requiring levels of <6.5  % 
(48 mmol/ml). Coronary arterial disease inclusion crite-
ria were non-fatal acute myocardial infarction, hospital-
ised acute coronary syndrome, resuscitated cardiac arrest 
(not attributed to non CAD causes), coronary artery 
bypass graft (CABG) or any other coronary revascu-
larisation procedure. Cerebrovascular disease inclusion 
criteria were non-fatal strokes and transient ischemic 
attacks (TIA) confirmed by a specialist stroke physician. 
It excluded TIA not confirmed by specialist, haemor-
rhagic stroke, and stroke associated with a primary hae-
matological disease e.g. leukaemia, polycythaemia, blood 
disease, tumours, trauma or surgical procedures. Lower 
extremity arterial disease (LEAD) inclusion criteria were 
clinical intermittent claudication with either ankle-bra-
chial pressure index (ABPI) <0.9, abnormal toe systolic 
pressure, pulse volume recordings, transcutaneous oxy-
gen measurements, vascular imaging, or prior correc-
tive surgery, angioplasty or above ankle amputation (see 
Additional file 1: Table S1 for tabulated inclusion criteria 
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for the cardiovascular disease groups). Exclusion crite-
ria included the presence of metallic implants, history of 
claustrophobia, pregnancy, renal replacement or eGFR 
<30 ml/min/1.73 m2, and therapy for any chronic inflam-
matory disease, atrial fibrillation or malignancy.
Magnetic resonance imaging
Images were acquired on a 32 RF receiver channel, 
3  Tesla MRI scanner (Magnetom Trio, Siemens, Erlan-
gen, Germany). For whole body coverage, a combination 
of six RF coils including head matrix, neck matrix, spine 
matrix, two body matrix and peripheral angiography 
phased array RF surface coils were used. Subjects where 
placed supine, head first into the magnet bore. The imag-
ing protocol was carried out in three phases: (1) MRA of 
the thoracic and neck, and distal lower limbs, (2) CMR 
including late gadolinium enhancement (LGE) and (3) 
MRA of the abdomen, pelvis and proximal lower limb.
Whole body magnetic resonance angiography protocol
Whole body magnetic resonance angiography (WB-
MRA) images involved the acquisition of four over-
lapping 3D data sets using a coronal spoiled FLASH 
sequence (repetition time TR  =  2.6–3.47  ms; echo 
time TE  =  0.96–1.21  ms; flip angle  =  16°–37°; pixel 
area  =  1.1–1.5  mm2 and slice thickness  =  1–1.4  mm, 
slight variation according to station and participant body 
habitus). Anatomical paired images were acquired pre- 
and post-contrast from four anatomically distinct sta-
tions—head, neck and thorax (station 1), abdomen and 
pelvis (station 2), upper legs (stations 3) and lower legs 
(station 4). 0.5 M gadoterate meglumine (Guerbet, Ville-
pinte, France) was administered by intravenous injec-
tion into antecubital fossa using a Spectris Solaris power 
injector (MedRad, Pittsburgh, USA) at a rate of 1.5 ml/s, 
followed by a 20  ml bolus of saline. A dual injection, 
two stage acquisition with uptitring of contrast volume 
was performed due to the benefits of this technique on 
image quality over a single injection technique [10, 11]. 
Stations 1 and 4 pre-contrast images were acquired fol-
lowing which post-contrast images were acquired after 
an injection of 10 ml gadoterate meglumine with a 20 ml 
saline flush, both administered at 1.5 ml/s. Cardiac MRI 
was performed after this first injection before stations 2 
and 3 image acquisition began. Pre contrast images were 
acquired of both stations following which post-contrast 
images were acquired after an injection of 15 ml gadoter-
ate meglumine and 20  ml saline flush administered at 
1.5 ml/s.
Cardiac magnetic resonance (CMR) protocols
Cardiac magnetic resonance (CMR) imaging utilised 
a spine matrix and six-element body array matrix RF 
coils. TurboFLASH two-chamber, four-chamber and 
short axis localiser, and two-chamber and four-chamber 
cine images were acquired. Left ventricular assessment 
involved the acquisition of a horizontal long axis, verti-
cal long axis and stacked short axis cine images with 
repeated end-expiratory breath-holds, from the atrio-
ventricular ring to the apex. These were acquired using a 
CINE TrueFISP sequence with retrospective ECG-gating 
(repetition time TR = 3.4 ms; echo time TE = 1.48 ms; 
flip angle  =  50°–60°; pixel area  =  1.4  mm  ×  1.9  mm; 
slice thickness  =  6  mm; inter-slice gap  =  4  mm). Ten 
minutes after the injection of the first dose of contrast 
agent the LGE images were acquired using a 2D phase 
sensitive inversion recovery (PSIR) sequence (repetition 
time TR = 846.4/5.21 ms; echo time TE = 1.99 ms; flip 
angle = 200; pixel area = 1.4 mm × 1.9 mm; slice thick-
ness = 6 mm; inter-slice gap = 4 mm). The mean inver-
sion time (TI) was 376 ms (range 300–450 ms).
WB‑MRA image analysis
The 3D WB-MRA datasets were viewed offline (Care-
stream PACS Client Suite Version 10.1 sp1, Roches-
ter, NY, USA) as source images using both multi-planar 
reconstruction (MPR) and maximum intensity projec-
tions (MIP) by a radiologist (JRWM) with experience 
of reporting over 400 whole body magnetic resonance 
angiograms. The radiologist was blinded to the partici-
pants’ clinical history during image analysis. The arterial 
network was divided into 31 vessel segments extend-
ing from the distal internal carotid arteries to the distal 
points of the calf vessels (Fig.  1). Each arterial segment 
was visually inspected and assessed as either ‘diagnostic’ 
or ‘non-diagnostic’ depending on image quality and the 
clarity of vascular structure. Non-diagnostic segments 
were assigned as non-interpretable. The diagnostic seg-
ments were scored according to the degree of narrowing 
of the lumen diameter, with stenosis graded at the nar-
rowest part of the vessel. Where more than one stenosis 
was present in any vessel, the most severe stenosis was 
used to score the vessel. Categorical scores from 0 to 4 
were allocated to each vessel segment, where 0, segment 
with no stenosis; 1, <50  % stenosis; 2, 51–70  % steno-
sis; 3, 71–99 % stenosis; 4, vessel occlusion (Fig. 2). The 
‘standardised atheroma score’ (SAS) was calculated by 
summing each individual segment’s stenosis score, and 
divided by the number of diagnostic segments (n) before 
dividing by 4 which is the maximum potential score 
(Eq. 1): [7, 12].
The 31 vessel segments were subdivided into five ana-
tomical territories: (1) the head and neck arteries, (2) 
(1)SAS =
[(
MRA score
n
)
÷ 4
]
× 100
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Fig. 1 Whole body angiogram with stations and vascular territories described
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the aorta, (3) the abdominal arteries, (4) the ilio-femoral 
arteries and (5) Popliteal and infrageniculate arteries 
(Fig. 1). Regional SASs were calculated for each anatomi-
cal territory.
20 datasets were chosen at random and rescored by the 
same observer to derive intra-observer agreement.
CMR image analysis
Left ventricular analysis images were analysed offline 
using Argus software (Siemens, Erlangen, Germany) by 
an experienced researcher (SZM). Segmentation involved 
tracing endocardial and epicardial contours on the short-
axis left ventricle images at end-diastolic and end-sys-
tolic phases of the cardiac cycle. Papillary muscles were 
treated as part of the blood pool volume unless they were 
indistinguishable from the myocardial wall, and then they 
were assigned as left ventricle muscle. The left ventricu-
lar mass (LVM), stroke volume (LVSV), ejection fraction 
(LVEF), end-diastolic (LVEDV) and end-systolic volumes 
(LVESV) were determined using algorithm based on 
the Simpson rule. Results were normalised to body sur-
face area using the DuBois formula [13]. Left ventricular 
mass volume ratio (LVMVR) was calculated as LVEDV/
LVM. Left ventricular global function index (LVGFI) was 
calculated as LVGFI = (LVSV/LV global volume) × 100, 
where LV global volume was defined as the sum of the 
LV mean cavity volume [(LVEDV + LVESV)/2] and the 
myocardium volume [14]. The PSIR sequences of the left 
ventricle were inspected for evidence of late gadolinium 
enhancement (LGE) using an imaging workstation (Care-
stream, Rochester, NY, USA). 10 datasets were chosen 
at random and rescored by the same observer to derive 
intra-observer agreement.
Statistical methods
Descriptive statistics were used for the analysis of the 
demographic and clinical features of the cohorts with 
data expressed as mean  ±  standard deviation (SD) for 
normally distributed data, and median (interquartile 
range) for non-normal distributed data. Normality tests 
were performed; if the test failed, where possible stand-
ard transformations such as square root, reciprocal or 
logarithmic transforms were used to generate a Gaussian 
distribution. To test the null hypothesis to determine if 
samples originate from the same distribution, the one-
way analysis of variance (ANOVA) with the Bonferroni 
post hoc adjustment was used for the parametric data 
and Kruskal–Wallis ANOVA by ranks was used for the 
non-parametric data. ANCOVA was performed to con-
firm differences between the groups with the WB-SAS 
and LVM used separately as the dependant variables cor-
recting for age, sex, BMI, history of hypertension and 
smoking status. Two-way random effect absolute agree-
ment single measure intraclass correlation co-efficient 
(ICC) was performed to assess intra-observer consist-
ency of the WB-SAS and LV metrics. All data were ana-
lysed using SPSS statistical package (version 21.0, SPSS 
Inc. Chicago, IL, USA). Significance was assumed when 
Fig. 2 MRA visualization of the iliac arteries demonstrating examples of each of the five categorical vessel scores. a Grade 0. b Grade 1—dif‑
fuse irregularity of the vessel wall, none of which is causing >50 % stenosis. c Grade 2—50–70 % stenosis in the proximal external iliac. d Grade 
3—>70 % stenosis in the common iliac. e Grade 4—complete occlusion of the external iliac just after the bifurcation of the common iliac with 
compensatory dilation of the internal iliac artery evident
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p  <  0.05. A statistician from the Dundee Epidemiology 
and Biostatistics Unit (PR) provided statistical support.
Results
Of the 148 participants who completed the study 
protocol, 87 (61  %) were male with a mean age was 
64 ± 8.2 years (see Table 1 for full demographic details). 
The group with cardiovascular disease and diabetes had 
a significantly greater proportion of males, while the 
healthy volunteers had a significantly lower BMI and 
prevalence of hypertension compared to the other three 
groups. Other than these there were no statistically sig-
nificant differences in the demographic metrics between 
each of the groups. In particular there was no difference 
in duration of diabetes, or in HbA1c between the dia-
betic groups with and without history of cardiovascular 
disease.
On WB-MRA analysis, 4564 of the 4588 vessel seg-
ments (31 segments in 143 patients) evaluated were 
graded as ‘diagnostic’ quality, giving a diagnostic rate of 
99.5  %. 24 segments in six examinations were rated as 
‘non-diagnostic’ due to movement artefact or incomplete 
vessel visualisation. 961 (21.1  %) of the 4564 WB-MRA 
diagnostic segments had evidence of luminal narrow-
ing: 769 (10.3 %) had stenosis below 50 %, 75 (1.6 %) had 
stenosis between 50 and 70  %, 60 (1.3  %) had stenosis 
between 70 and 99 %, and 57 (1.2 %) had complete occlu-
sion. 135 participants (91 %) had evidence of at least one 
stenotic vessel (Table 2).
Those with cardiovascular disease without diabe-
tes had the highest whole body standardised atheroma 
score (WB-SAS) of 10.1 (0–39.5) followed by those with 
cardiovascular disease and diabetes with a WB-SAS of 
4 (0–41.1). The normal healthy volunteer group had the 
lowest WB-SAS of 2.4 (0–19.4), which was slightly lower 
than those with diabetes but no cardiovascular disease. 
The WB-SAS of the two cardiovascular groups (Groups 1, 
3) was significantly higher than those of the healthy dia-
betic and healthy control groups (p ≤ 0.05) (Fig. 3). On 
univariate analysis of covariance after accounting for age, 
Table 1 Population demographics of the participants
Values expressed as mean ± SD, or N (%)
Group 1, T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, healthy volunteers
BMI body mass index, BP blood pressure, CAD coronary artery disease, LEAD lower extremity arterial disease
* p < 0.05 compared to Group 4
** p < 0.05 compared to Groups 2 and 4
^ p < 0.05 compared to Groups 3 and 4
a Groups add up to >100 % as several individuals had more than one prior cardiovascular event
Group 1 CVD+ DM+ Group 2 CVD− DM+ Group 3 CVD+ DM− Group 4 CVD− DM− p value
N 34 55 30 29
Male (%) 76* 56 73 41 0.015
Age (years) 65 ± 7 63 ± 8 67 ± 9** 62 ± 8 0.03
BMI (kg/m2) 31 ± 4* 30 ± 6* 29 ± 4 28 ± 4 0.009
Hypertension 24 (75 %)* 34 (62 %)^ 27 (90 %)* 7 (24 %) <0.001
Systolic BP 132 ± 13 137 ± 14 137 ± 15 133 ± 15 0.4
Diastolic BP 74 ± 8 78 ± 8 76 ± 9 78 ± 9 0.25
LDL‑cholesterol (mmol/l) 1.69 ± 0.5* 1.98 ± 0.8* 1.97 ± 0.6* 2.80 ± 0.8 <0.001
HDL‑cholesterol (mmol/l) 1.11 ± 0.3* 1.26 ± 0.3* 1.27 ± 0.5 1.53 ± 0.4 0.001
Triglycerides (mmol/l) 2.08 ± 1.0 1.70 ± 0.8 1.60 ± 0.9 1.76 ± 1.0 0.18
Creatinine 86.3 ± 24 73.1 ± 17 80.7 ± 17 70.6 ± 15 0.003
HbA1c 7.3 (6–11)^ 7.3 (5–12)^ 5.7 (5–8) 5.6 (5–6) <0.001
Duration of diabetes (years) 10.4 ± 4.7 9 ± 6.2 0.3
Current/ex smoker (%) 72 49 60 52 0.37
Medications
 Antihypertensive therapy (%) 84** 56* 93** 28 <0.001
 Number antihypertensive agents 1.83 ± 1.0** 0.96 ± 1.0 1.93 ± 0.9** 0.39 ± 0.1 <0.001
 Statin 88* 73* 80* 25 <0.001
Prior cardiovascular eventsa
 CAD 75 77 0.88
 Cerebrovascular 19 23 0.66
 LEAD 19 17 0.83
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sex, BMI, history of hypertension and smoking status, 
the only significant difference that persisted was between 
the non-diabetic cardiovascular disease group and the 
healthy controls. There were no significant differences in 
WB-SAS between the cardiovascular disease groups with 
and without diabetes, nor between the diabetics without 
cardiovascular disease and the healthy controls.
Indexed left ventricular mass (LVM) and prevalence of 
late gadolinium enhancement was significantly higher in 
the two cardiovascular disease cohorts (p  <  0.05) com-
pared to both the non-cardiovascular disease groups (see 
Table  2). Left ventricular mass volume ratio (LVMVR) 
was significantly higher in the cardiovascular disease 
group with diabetes compared with the healthy controls 
but not compared to either of the other two groups. Dif-
ference between groups for LVM and LVMVR were lost 
after accounting for age, sex, BMI, history of hyperten-
sion and smoking status on analysis of covariance. There 
was no significant difference in left ventricular end dias-
tolic volume (EDV) end systolic volume (ESV), stroke 
volume (SV), ejection fraction (EF) or left ventricular 
global function index (LVGFI) between the 4 groups. 
There were no significant differences in any of the LV 
metrics between subjects with diabetes and those with-
out when history of cardiovascular disease was accounted 
for.
Left ventricular myocardial contrast enhancement was 
observed in 29 % of type 2 diabetic with CVD (Group 1), 
Table 2 Comparison of MRI metrics between the four groups
Values expressed as mean ± SD, median (range) or N (%)
Group 1, T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, healthy volunteers
SAS standardised atheroma score, WB whole body, LVM left ventricular massa, EDV end diastolic volumea, ESV end systolic volumea, EF ejection fraction, SV stroke 
volumea, LVMVR left ventricular mass volume ratio, LVGFI left ventricular global function index, LGE late gadolinium enhancement
* p < 0.05 when compared to Group 2
** p < 0.05 when compared to Groups 2 and 4
^ p < 0.05 when compared to Group 4
a Normalised to body surface area
Group 1 CVD+ DM+ Group 2 CVD− DM+ Group 3 CVD+ DM− Group 4 CVD− DM− p value
WB‑MRA
 WB SAS 4 (0–41.1)** 3.23 (0–19.4) 10.1 (0–39.5)** 2.4 (0–19.4) <0.001
 Head/neck‑SAS 5.6 (0–11.8)^ 2.8 (2.8–5.6) 5.6 (2.8–9.0) 0 (0–5.6) 0.024
 Aorta‑SAS 8.3 (0–16.7) 0 (0–8.3) 16.7 (8.3–16.7)** 8.3 (0–8.3) <0.001
 Abdomen‑SAS 0 (0–10) 0 (0–5) 5 (0–15)* 0 (0–10) 0.02
 Ilio‑femoral‑SAS 4.2 (0–22.9)* 4.2 (0–8.3) 18.8 (4.2–30.2)** 0 (0‑10.4) <0.001
 Run off‑SAS 4.7 (0–19.5)** 0 (0–3.1) 3.1 (0–25.8)** 0 (0–1.6) <0.001
 Normal vessels 765** 1432 627** 779 <0.001
 Vessels with 1–50 % 
stenosis
190 251 221** 107 0.008
 Vessels with 51–70 % 
stenosis
38** 7 24* 6 <0.001
 Vessels with 71–99 % 
stenosis
24* 4 26** 6 0.002
 Occluded vessels 22 4 30** 1 <0.001
 Abnormal vessels 8.5** 5 10.1** 4.1 <0.001
 N (%) with >50 % stenosis 
in any vessel
19 (56 %)** 12 (21.8 %) 20 (66.7 %)** 11 (38 %) <0.001
Cardiac MRI
 LVM (g/m2) 60.5 (45–86)** 54.4 (39–95) 60 (41–86)** 50.9 (35–73) 0.001
 LVEDV (ml/m2) 71.2 ± 14.5 66.9 ± 12.8 74.9 ± 19.8 68.7 ± 9.9 0.096
 LVESV (ml/m2) 24.4 (9–58) 22.4 (11–55) 25.1 (11–90) 24.9 (13–38) 0.52
 LVEF (%) 64.6 ± 11.3 65.9 ± 8.8 64.3 ± 10.3 66 ± 7.4 0.83
 LVSV (ml/m2) 45.3 ± 9.2 43.7 ± 8.2 47 ± 8.2 45.1 ± 7.2 0.37
 LVMVR (g/ml) 0.88 ± 0.14^ 0.84 ± 0.13 0.83 ± 0.16 0.78 ± 0.14 0.036
 LVGFI 0.43 ± 0.09 0.45 ± 0.08 0.44 ± 0.08 0.47 ± 0.07 0.21
 LGE (%) 9 (29)* 3 (5.5) 11 (38)* 0 (0) <0.001
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5.5 % of type 2 diabetic without CVD (Group 2), 39 % of 
non-diabetics with CVD (Group 3), and 0 % of non-dia-
betics with no CVD (Group 4) (Table 2). Clinical records 
showed that all 11 non-diabetic Group 3 subjects with 
positive LGE had a history of coronary heart disease. 
However only eight of the nine diabetic Group 1 subjects 
had a history of coronary heart disease, with one report-
ing known LEAD but no previous history of coronary 
artery disease in keeping with a silent myocardial infarct. 
3 (5.5  %) participants with diabetes without any history 
of cardiac event demonstrated myocardial scarring typi-
cal of a myocardial infarction, the whole body SAS of 
these three individuals was significantly higher than the 
remainder of the diabetes group without history of car-
diovascular disease [7.7 (4–19) vs. 2.8 (0–17), p = 0.024].
Both SAS and the LV metrics demonstrated good 
agreement on intra-observer analysis: SAS ICC 0.93 
(95  % CI 0.83–0.97, p  <  0.001); EF ICC 0.98 (95  % CI 
0.85–0.99, p < 0.001); EDV ICC 0.98 (95 % CI 0.56–0.99, 
p < 0.001), SV ICC 0.98 (95 % CI 0.92–0.99, p < 0.001); 
LVM ICC 0.99 (95  % CI 0.98–0.99, p  <  0.001). This is 
consistent with previous work where intra- and inter-
observer variability for both readers and techniques has 
been described in more detail [7].
Intra-observer variability was good for the WB-SAS 
(0.93 (95 % CI 0.83–0.97, p < 0.001).
Discussion
In this study we have shown that in non-diabetics the 
global atheroma burden as measured by whole body 
MRA is significantly higher in individuals with clinically 
evident cardiovascular disease compared with diabetic 
and non-diabetic controls. However when looking at 
those with type 2 diabetes there was significant overlap in 
the atheroma burden between the groups with and with-
out cardiovascular disease, and no significant difference 
between either groups compared with healthy controls. 
This is a surprising and, given the known effects of dia-
betic status on cardiovascular events, a slightly counter-
intuitive finding.
From the current observations it appears that either 
cardiovascular events occur at a lower atheroma bur-
den in those with type 2 diabetes compared with non-
diabetics, or that there is a clinical bias in the suspicion 
of vascular events in those with type 2 diabetes result-
ing in diagnosis of cardiovascular events at a lower dis-
ease threshold. Atherosclerotic plaques in those with 
diabetes have a larger necrotic core, a thinner capsule 
and impaired vascular repair mechanisms—all of which 
increase the likelihood of rupture [15–17]. Given that the 
majority of coronary and cerebrovascular events occur 
secondary to ruptured atherosclerotic plaque [18, 19], it 
is therefore feasible that cardiovascular events occur at a 
lower atheroma burden in a diabetic population due to a 
greater propensity of the plaques they do have of ruptur-
ing and occluding arteries. In addition diabetes is asso-
ciated with impaired microcirculatory function, which 
itself is associated with a higher risk for future cardiovas-
cular events, therefore potentially reducing the atheroma 
burden necessary to elicit a cardiovascular event [20, 21].
A previous study using whole body atheroma burden 
by Weckbach et al. [22] demonstrated an increased bur-
den of vascular disease in a diabetic cohort compared 
with a healthy population. However given that the dia-
betic group included patients with cardiovascular dis-
ease while their control group excluded patients with 
cardiovascular disease it is difficult to extricate the effects 
of diabetes per se on atheroma burden, especially given 
that in our study we found a higher burden of atheroma 
in those with cardiovascular disease compared to those 
without. A separate subgroup analysis by the same group 
showed that those with diabetes with metabolic syn-
drome had a significantly higher atheroma burden than 
those without, but did not compare those with diabetes 
but without metabolic syndrome to the healthy cohort 
[8]. In a population based study of 306 70-year-old 
Hansen et al. found no association between diagnosis of 
diabetes and atheroma burden, however found a relation-
ship between the HOMA insulin resistance index and 
atheroma score [23]. Lehrke et al. [24] also found no dif-
ference in atheroma burden between diabetic and non-
diabetic groups, although the study only had 13 diabetic 
patients in their cohort. Consistent with these previous 
studies we have found that when diabetic patients are 
compared with patients without diabetes after stratifying 
Fig. 3 Box plot comparing SAS between the four groups. Group 1, 
T2DM and CVD; Group 2, T2DM, no CVD; Group 3, CVD; Group 4, 
healthy volunteers. Box 1st–3rd quartiles with thick line representing 
the group median. Open circle and asterisk outliers
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them based on cardiovascular history that no difference 
in atheroma burden was observed. A similar lack of dif-
ference in stenotic atheroma burden has been observed 
on invasive coronary angiography between groups with 
and without type 2 diabetes [25, 26].
While our criteria for recruitment into the cardiovas-
cular disease groups was strict it does not preclude the 
effects of referral bias in the type 2 diabetes cohort. Given 
the known increased cardiovascular risk in type 2 diabe-
tes it is possible that the threshold for eliciting a referral 
for cardiovascular related investigations for symptoma-
tology occurs at an earlier stage in those with diabetes 
than those without thus resulting in a lower observed 
atheroma burden. Greater prescription of antihyperten-
sive and statin therapy was observed in both the groups 
with diabetes compared with the healthy controls, which 
if initiated early in the disease processes could also have 
attenuated disease progression given the known effects of 
statins on plaque volume [27].
Less likely is that the lack of difference in observed ath-
eroma burden between the groups may lie in the lume-
nographic assessment that WB-MRA provides, with lack 
of ability to quantify non stenotic atheroma with positive 
remodelling. When considering coronary artery disease, 
catheter angiography has demonstrated no significant 
difference between diabetic and non-diabetic cohorts in 
stenotic disease burden [25, 26], however when intra-
vascular ultrasound is used a greater plaque area encas-
ing diffusely narrower arteries is observed [28]. Also 
CT coronary artery calcium scoring and CT coronary 
angiography, which can visualise extraluminal plaque, 
demonstrate higher plaque burden in diabetic cohorts 
[29]. The lumenographic nature of the technique is an 
acknowledged limitation [30], however no other widely 
available technique is yet available to quantify this metric 
throughout the entire body. Furthermore, atherosclero-
sis with positive vascular remodelling is a relatively early 
phenomenon in the development of plaque, therefore 
even if this were to be missed it would not explain the 
discrepancy in stenotic plaque burden.
Within the healthy diabetic cohort we observed a 5 % 
prevalence of silent myocardial infarct. This is in keep-
ing with prior studies showing an incidence of silent 
infarcts in diabetic populations to range from 2.7 to 17 % 
depending on the method used and cohort studied [31–
33]. Those with silent myocardial infarcts had a signifi-
cantly higher atheroma burden which is consistent with 
other groups results showing that those with an elevated 
atheroma burden were more likely to have obstructive 
coronary artery disease and develop major adverse car-
diovascular events at follow-up [9, 24]. This finding adds 
further support of the prognostic importance of the 
whole body atheroma burden on future cardiovascular 
events as evidenced by two prior studies showing the 
stenotic atheroma burden on WB-MRA to have superior 
prognostic efficacy over traditional risk scores, carotid 
intima media thickness and ankle-brachial pressure index 
[9, 34].
There are several limitations of the current study. 
As previously discussed whole body MRA is a lume-
nographic technique, and therefore may miss plaque 
with vascular remodelling which maintains the luminal 
diameter. Our scoring system prescribes no weighting 
to specific vessels, or to vessels with multisite stenosis. 
Long-term studies are required to assess the prognostic 
significance of disease of individual vessels, and how mul-
tiple lesions compare with single lesions in these differ-
ent groups. Finally the coronary vessels are not assessed 
in the current study protocol. MRI coronary angiography 
holds some promise but is still some way off routine clini-
cal use [35], however as this continues to improve incor-
poration of this in WB-CVMR will become an interesting 
avenue for exploration in the future.
Conclusion
Global atheroma burden was significantly higher in those 
with known cardiovascular disease and without diabetes 
but not in those with diabetes and cardiovascular dis-
ease suggesting that cardiovascular events may occur at a 
lower atheroma burden in diabetes.
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